The FDA has authorized marketing of Essilor Stellest spectacle lenses by EssilorLuxottica, allowing the first eyeglass lenses capable of slowing pediatric myopia progression to be sold in the U.S.
The lenses were approved through the FDA’s de novo premarket review pathway after being granted breakthrough device designation in April 2021.
“The ability to control, and in some cases even reverse, myopia has been mission critical for eye doctors for many decades,” Dominick M. Maino, OD, Med, FAAO, FCOVD-A, emeritus professor at the Illinois College of Optometry/Illinois Eye Institute, told Healio.